ERBB2 and breast carcinoma: However, most of our patients with HR+/HER2‐, early‐stage breast cancer (69.0% N0 and 98.1% N1) had received chemotherapy in this study, which may due to the inadequate application of Oncotype Dx, EndoPredict, Mammaprint and other gene expression assays in real‐world practice of southern China.